文献速递疼痛医学

冷却射频消融在慢性骶髂关节疼痛治疗中展现持久临床效用:随机多中心比较有效性交叉研究观察期12个月随访结果

Cooled radiofrequency ablation provides extended clinical utility in the management of chronic sacroiliac joint pain: 12-month follow-up results from the observational phase of a randomized, multicenter, comparative-effectiveness crossover study.
PubMed 文献 · Reg Anesth Pain Med · 2026-06-05

该随机多中心比较有效性研究纳入210例注射确认的骶髂关节疼痛患者,随机接受L5背支及S1-S3/4外侧支冷却射频消融(CRFA)或标准药物管理(SMM),SMM效果不佳者3个月时交叉接受CRFA。12个月时CRFA组平均NRS疼痛评分从基线6.4±1.4降至3.5±2.6,57.4%(35/61)患者疼痛下降≥2分或30%;交叉组55.6%(35/63)达到相同标准,生活质量与功能均改善,无CRFA相关严重不良事件。

要点

  • 单次CRFA可为骶髂关节疼痛提供持续12个月的临床显著改善。
  • 12个月时CRFA组57.4%患者疼痛下降≥2分或30%,交叉组为55.6%。
  • 未报告CRFA操作相关的严重不良事件。

核心结论

  • CRFA治疗骶髂关节疼痛可提供临床显著且持续12个月的改善,无论患者此前是否接受过SMM治疗。

研究设计与样本

  • 随机、多中心、比较有效性交叉研究,纳入210例注射确认的骶髂关节疼痛且对预后性外侧支阻滞有反应的患者。
  • 患者随机接受L5背支及S1-S3/4外侧支CRFA或标准药物管理(SMM),SMM效果不满意者在3个月时交叉接受CRFA。
  • 随访时间点为1、3、6、9和12个月。

主要发现

  • 12个月时CRFA组平均NRS疼痛评分从基线6.4±1.4降至3.5±2.6,57.4%(35/61)患者疼痛下降≥2分或30%。
  • 交叉组在交叉术后12个月时55.6%(35/63)患者达到相同标准,平均LBP从6.1±1.5降至3.4±2.5。
  • 12个月时EuroQoL-5D-5L评分改善:原CRFA组平均变化+0.22±0.27,交叉组+0.21±0.33。
  • Oswestry功能障碍指数(ODI)从基线改善:CRFA组12.4%±14.7,交叉组13.7%±17.1。
  • 未报告CRFA操作相关的严重不良事件。

关键数值与推荐

  • 应答者定义为平均每日NRS疼痛评分下降≥30%或≥2分,且患者整体印象变化量表评分≥5/7(中等改善)。

临床怎么用

  • 对于注射确认的骶髂关节疼痛患者,可考虑单次CRFA治疗以获得持续12个月的疼痛缓解和功能改善。
  • CRFA可作为SMM效果不佳后的后续治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Sacroiliac joint (SIJ) pain comprises up to 30% of cases of mechanical low back pain (LBP), the leading cause of disability worldwide. Despite sacral lateral branch cooled radiofrequency ablation (CRFA) showing efficacy in clinical trials, there is a lack of comparative-effectiveness long-term follow-up. METHODS: In this randomized, multicenter, comparative-effectiveness study, 210 patients with injection-confirmed SIJ pain who responded to prognostic lateral branch blocks were randomly assigned to receive CRFA of the L5 dorsal ramus and S1-S3/4 lateral branches or standard medical management (SMM) consisting of pharmacotherapy, physical therapy, injections, and integrative therapies. Patients were followed up at 1, 3, 6, 9, and 12 months, with participants reporting unsatisfactory SMM outcomes being allowed to crossover (XO) and receive CRFA at 3 months. The primary outcome measure was the mean change in average LBP score on a 0-10 Numeric Rating Scale (NRS), with secondary outcomes including measures of quality of life (QoL) and function. A responder was defined as a participant who experienced a ≥30% or ≥2-point decrease in average daily NRS pain score coupled with a score ≥5 out of 7 (moderately better) on the Patient Global Impression of Change scale. RESULTS: At 12 months, the mean NRS pain score declined from a baseline of 6.4±1.4 to 3.5±2.6, with 57.4% (35/61) of participants in the randomized CRFA cohort experiencing a ≥2-point or 30% decrease in average LBP from baseline. In the crossover cohort, 35/63 (55.6%) subjects had the same experience 12 months following the XO procedure; in the XO group, the mean LBP decreased from 6.1±1.5 to 3.4±2.5. Patients also experienced clinically meaningful improvements in QoL via EuroQoL-5D-5L at 12 months (mean change of +0.22±0.27 in the originally-treated CRFA group and +0.21±0.33 in the XO group). Oswestry Disability Index (ODI) scores also improved by 12.4%±14.7 (CRFA) and 13.7%±17.1 (XO) from baseline at study-end. No serious adverse events related to the CRFA procedure were reported. CONCLUSION: CRFA in patients with SIJ pain provided clinically significant and sustained improvements for 12 months following a single CRFA treatment, regardless of previous SMM treatment. TRIAL REGISTRATION NUMBER: NCT03601949.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Cohen SP, Kapural L, Kohan L, et al. Cooled radiofrequency ablation provides extended clinical utility in the management of chronic sacroiliac joint pain: 12-month follow-up results from the observational phase of a randomized, multicenter, comparative-effectiveness crossover study. Reg Anesth Pain Med. 2026. PMID: 40089310. doi:10.1136/rapm-2024-106315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。